<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923987</url>
  </required_header>
  <id_info>
    <org_study_id>K-1208-001-002</org_study_id>
    <secondary_id>KCT0000525</secondary_id>
    <secondary_id>K-1208-001-002</secondary_id>
    <nct_id>NCT01923987</nct_id>
  </id_info>
  <brief_title>Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis</brief_title>
  <official_title>Multicenter Phase II Study of Short Course Radiotherapy Followed by Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Cancer Center Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of Korea, Yeouido St. Mary`s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongtan Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Koreran Society of Coloproctology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of Korea, Seoul St. Mary`s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea Cancer Center Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radical treatment of primary rectal cancer with synchronous distant metastases includes
      surgical resection of primary and metastatic lesion. However, primary rectal cancer in case
      of metastasized disease are often locally advanced disease and need downsizing before
      surgery. It is reported that pelvic recurrence rates and distant metastasis rates outside
      liver are 30~35% and 60%, respectively. Therefore, combined treatment with radiotherapy and
      chemotherapy is used. However, the sequence of treatment modalities is not yet definitely
      established and preoperative chemoradiotherapy and surgical resection is accepted as an
      option of treatment. Conventional long course chemoradiotherapy delays administration of
      full-dose chemotherapy, and metastatic lesion can be progressed during chemoradiotherapy. In
      present study, we evaluate the efficacy of short course radiotherapy (SCRT) followed by
      full-dose chemotherapy with delayed surgical resection of the primary tumor and metastases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Expected average of 12 weeks (after resection)</time_frame>
    <description>R0 resection rate of primary and metastatic lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>2 years</time_frame>
    <description>From the first date of radiotherapy to the date of death or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rate</measure>
    <time_frame>2 years</time_frame>
    <description>From the first date of radiotherapy to the date of first failure or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor regression grade</measure>
    <time_frame>Just after resection &amp; pathologic report</time_frame>
    <description>Tumor regression grade of primary lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Liver Metastasis</condition>
  <condition>Lung Metastasis</condition>
  <arm_group>
    <arm_group_label>SCRT/ChemoTx with Delayed Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short course radiotherapy (25 Gy in 5 fractions) followed by intensive chemotherapy, compromising of FOLFOX of FOLFIRI (+-Bevacizumab or Cetuximab), with delayed surgery for rectal cancer with synchronous distant metastasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Short Course Radiotherapy</intervention_name>
    <description>Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days</description>
    <arm_group_label>SCRT/ChemoTx with Delayed Surgery</arm_group_label>
    <other_name>Upfront Short-Course Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1
Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1
Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2
5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).
Bevacizumab 5 mg/kg IV over 90 mins on Day 1
Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.
FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses
Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)</description>
    <arm_group_label>SCRT/ChemoTx with Delayed Surgery</arm_group_label>
    <other_name>FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Delayed Surgery</intervention_name>
    <description>If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).</description>
    <arm_group_label>SCRT/ChemoTx with Delayed Surgery</arm_group_label>
    <other_name>Total (or Tumor-specific) mesorectal excision</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed adenocarcinoma of rectum

          -  Lower margin of tumor within 12 cm from anal verge

          -  Clinically locally advanced (T3-4 or N1-2) disease

          -  Potentially resectable and synchronous distant metastases in liver and/or lung. The
             resectability of metastatic lesions is determined by size, number, location, general
             condition, liver function, and lung function.

          -  Over 18 years

          -  Eastern Cooperative Oncology Group performance status 0-2

          -  Proper organ function (Hemoglobin ≥ 10 g/dl, Absolute neutrophil count (ANC) ≥
             1,500/mm3, Platelet ≥ 100,000/mm3, Creatinine ≤ 1.5 mg/dl, Clearance of creatinine &gt;50
             ml/min using Cockcroft-Gault formula, Bilirubin ≤ 1.5 x upper limit of normal (ULN),
             Liver enzyme (Aspartate aminotransferase/Alanine transaminase/Alkaline phosphatase) ≤
             2.5 x ULN)

          -  Subject who should sign on the informed consent form before participate the trial.

        Exclusion Criteria:

          -  Metastases in other organ except liver or lung

          -  History of other type of malignancies within 3 years other than non-melanoma of the
             skin or carcinoma in situ of cervix

          -  Hereditary colorectal cancer (FAP, HNPCC, and etc)

          -  Bowel obstruction or impending bowel obstruction

          -  Uncontrolled severe illness, unsuitable to chemoradiotherapy (within 6 months,
             myocardial infarct, unstable angina, heart failure, uncontrolled arrhythmia,
             uncontrolled epilepsy, central nervous system disease, psychological disorder, and
             etc)

          -  Subject pregnant or breast feeding, or incapable of appropriate contraception

          -  Unresected synchronous colorectal cancer

          -  History of prior pelvic radiotherapy

          -  History of prior chemotherapy for colorectal cancer

          -  Great surgery within 4 week before study enrollment

          -  Participant in other trial within 4 week before study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun Mi Moon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea Cancer Center Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sun Mi Moon, MD, PhD</last_name>
    <phone>82-2-970-1237</phone>
    <email>msm386@yahoo.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Won Il Jang, MD, MS</last_name>
    <phone>82-2-970-1262</phone>
    <email>zzang11@kirams.re.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kyung Hee University Gangdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>139-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Mi Moon, MD, PhD</last_name>
      <phone>82-2-970-1237</phone>
      <email>msm386@yahoo.co.kr</email>
    </contact>
    <contact_backup>
      <last_name>Won Il Jang, MD, MS</last_name>
      <phone>82-2-970-1262</phone>
      <email>zzang11@kirams.re.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Sun Mi Moon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ui Sup Shin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Won Il Jang, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sun Hee Ji, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <last_update_submitted>April 21, 2016</last_update_submitted>
  <last_update_submitted_qc>April 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea Cancer Center Hospital</investigator_affiliation>
    <investigator_full_name>Sun Mi Moon</investigator_full_name>
    <investigator_title>Korea Cancer Center Hospital</investigator_title>
  </responsible_party>
  <keyword>Short course radiotherapy</keyword>
  <keyword>Modified FOLFOX6</keyword>
  <keyword>Delayed surgery</keyword>
  <keyword>Rectal cancer</keyword>
  <keyword>Synchronous metastasis</keyword>
  <keyword>Liver metastasis</keyword>
  <keyword>Lung metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

